Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Dear TrialNet Family,
As we announce the year one findings for the ATG-GCSF New Onset Study, I’d like to take a moment to give a big and well-deserved thank you to everyone who made this study possible:
Here we share with you our year one primary findings. We’ll be back with final study findings in early 2019.
Until then,Carla Greenbaum, M.D.
This study was designed to build on prior findings of a pilot study suggesting thymoglobulin (ATG) combined with pegylated granulocyte colony stimulating factor (GCSF) preserved insulin production for more than 1 year after treatment in people who had type 1 diabetes for 4 months to 2 years.
TrialNet researchers wanted to know if ATG alone or in combination with GCSF could slow insulin loss when started earlier. To find out, we enrolled 89 people between age 12 and 45 diagnosed with type 1 diabetes within the past 100 days.
Participants were divided into three groups: one group received ATG, one group received ATG combined with GCSF, and one group received a placebo (looks like the study drug but is inactive). Everyone is participating in the study for two years.
ATG-GCSF New Onset Study year one primary findings (one year after start of treatment) were presented at the 2018 ADA Scientific Sessions on June 25, 2018. Now, we share them with you.
In addition, TrialNet is continually planning and launching new studies. Also, we always encourage family members of people with T1D to get screened through the Pathway to Prevention study.
If you have questions about study results, please contact your study team or email@example.com.
I am a current TrialNet Participant
I am a member of the Media
I am a Health Care Provider
I am a Researcher and would like to use samples